Wells Fargo’s Genocea Biosciences, Inc. GNCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-16,463
| Closed | -$20K | – | 8044 |
|
|
2022
Q1 | $20K | Buy |
16,463
+7,001
| +74% | +$7.63K | ﹤0.01% | 6021 |
|
|
2021
Q4 | $11K | Sell |
9,462
-206
| -2% | -$307 | ﹤0.01% | 6520 |
|
|
2021
Q3 | $18K | Buy |
9,668
+136
| +1% | +$267 | ﹤0.01% | 6014 |
|
|
2021
Q2 | $22K | Buy |
9,532
+2
| +0% | +$5 | ﹤0.01% | 5867 |
|
|
2021
Q1 | $26K | Buy |
9,530
+3
| +0% | +$9 | ﹤0.01% | 6084 |
|
|
2020
Q4 | $23K | Buy |
9,527
+8
| +0.1% | +$18 | ﹤0.01% | 5829 |
|
|
2020
Q3 | $22K | Sell |
9,519
-781
| -8% | -$2.05K | ﹤0.01% | 5735 |
|
|
2020
Q2 | $23K | Sell |
10,300
-7,214
| -41% | -$16.6K | ﹤0.01% | 5674 |
|
|
2020
Q1 | $30K | Sell |
17,514
-3,367
| -16% | -$6.8K | ﹤0.01% | 5503 |
|
|
2019
Q4 | $43K | Sell |
20,881
-15,250
| -42% | -$36.2K | ﹤0.01% | 5557 |
|
|
2019
Q3 | $105K | Buy |
36,131
+2,500
| +7% | +$8.54K | ﹤0.01% | 5303 |
|
|
2019
Q2 | $132K | Buy |
33,631
+32,500
| +2,874% | +$170K | ﹤0.01% | 5183 |
|
|
2019
Q1 | $5K | Sell |
1,131
-125
| -10% | -$618 | ﹤0.01% | 5760 |
|
|
2018
Q4 | $3K | Buy |
1,256
+165
| +15% | +$821 | ﹤0.01% | 6181 |
|
|
2018
Q3 | $6K | Sell |
1,091
-125
| -10% | -$660 | ﹤0.01% | 6106 |
|
|
2018
Q2 | $8K | Sell |
1,216
-1,618
| -57% | -$12.1K | ﹤0.01% | 6019 |
|
|
2018
Q1 | $24K | Buy |
2,834
+1,062
| +60% | +$8.82K | ﹤0.01% | 5772 |
|
|
2017
Q4 | $17K | Sell |
1,772
-290
| -14% | -$2.92K | ﹤0.01% | 5827 |
|
|
2017
Q3 | $24K | Buy |
2,062
+1,562
| +312% | +$59.3K | ﹤0.01% | 5673 |
|
|
2017
Q2 | $21K | Buy |
500
+375
| +300% | +$18.1K | ﹤0.01% | 5625 |
|
|
2017
Q1 | $6K | Hold |
125
| – | – | ﹤0.01% | 6004 |
|
|
2016
Q4 | $4K | Hold |
125
| – | – | ﹤0.01% | 6010 |
|
|
2016
Q3 | $5K | Hold |
125
| – | – | ﹤0.01% | 5929 |
|
|
2016
Q2 | $4K | Sell |
125
-1,264
| -91% | -$46.3K | ﹤0.01% | 5872 |
|
|
2016
Q1 | $87K | Buy |
1,389
+138
| +11% | +$4.38K | ﹤0.01% | 4936 |
|
|
2015
Q4 | $52K | Hold |
1,251
| – | – | ﹤0.01% | 5267 |
|
|
2015
Q3 | $69K | Buy |
1,251
+885
| +242% | +$87.8K | ﹤0.01% | 5127 |
|
|
2015
Q2 | $40K | Buy |
366
+213
| +139% | +$19.8K | ﹤0.01% | 5391 |
|
|
2015
Q1 | $15K | Buy |
153
+5
| +3% | +$353 | ﹤0.01% | 5496 |
|
|
2014
Q4 | $8K | Hold |
148
| – | – | ﹤0.01% | 5735 |
|
|
2014
Q3 | $11K | Sell |
148
-987
| -87% | -$108K | ﹤0.01% | 5552 |
|
|
2014
Q2 | $170K | Buy |
+1,135
| New | +$172K | ﹤0.01% | 4448 |
|
Other funds holding GNCA
Wells Fargo's GNCA Position: Q2 2022 in Review
Wells Fargo sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 16,463 shares — an estimated $20K sold.
Wells Fargo first reported a position in GNCA in Q2 2014 and held it in 32 quarters. The position peaked at $170K in Q2 2014. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.
- Wells Fargo reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
- Wells Fargo sold 16,463 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $20K.
- Wells Fargo first reported a position in Genocea Biosciences, Inc. in Q2 2014 and held it in 32 quarters.
- Wells Fargo's Genocea Biosciences, Inc. position peaked at $170K in Q2 2014.
- 5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.
Based on Wells Fargo's 13F filing for Q2 2022, filed 12 Aug 2022.